CRL
Status-Quo-PlayerCharles River Laboratories
$178.34
+1.53%
as of 13 Apr
Power Core
The moat in one sentence: Charles River's power core is the regulatory and institutional trust embedded in decades of preclinical data packages accepted by global health authorities, creating switching costs that are invisible but structural.
Direction of Movement
Lateral Trajectory with Unresolved Structural Questions
ROC 200
+15.1%
CRL
Charles River Laboratories
$178.34
+1.53%
as of 13 Apr
DCF Fair Value: $119.10
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Charles River Laboratories International, Inc. is a leading provider of essential products and services that support pharmaceutical, biotechnology, and medical device companies in drug discovery, development, and manufacturing. It operates through three core segments: Research Models and Services, which supplies specialized animal models, insourcing solutions, and accelerator and development labs for preclinical research; Discovery and Safety Assessment, delivering regulatory-required safety testing for new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices; and Manufacturing Solutions, offering microbial solutions for in vitro testing and biologics solutions including testing services and avian vaccines. These offerings enable clients to advance therapies from early discovery through safety validation and production support, playing a critical role in the preclinical and clinical stages of the life sciences industry. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories International, Inc. serves a global market with a focus on high-quality, compliant research and testing services.